Zanubrutinib

Independent reference data for Zanubrutinib (CAS 1691249-45-2), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Zanubrutinib is indicated for the treatment of: - Mantle cell lymphoma (MCL) in adults who have received at least one prior therapy. - Waldenström’s macroglobulinemia in adults. - Relapsed or refractory marginal zone lymphoma (MZL) in adults who have received at least one anti-CD20-based regimen. - Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults. - Refractory or relapsed follicular lymphoma, in combination with [obinutuzumab], in adults who have received at least two prior systemicZanubrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of refractory mantle cell lymphoma. Zanubrutinib has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury although it may pose a risk for reactivation of hepatitis B in susceptible patients.

Synonyms and trade names

Zanubrutinib; 1691249-45-2; Brukinsa; BGB-3111; AG9MHG098Z; DTXSID701026208; zanubrutinibum; BTK-InhB; RefChem:57294; DTXCID701510461; Zanubrutinib [INN]; Zanubrutinib [USAN]; BGB3111; UNII-AG9MHG098Z; 1691249-45-2 (S-isomer); Zanubrutinib (BGB-3111)

GHS hazard classification

Reported hazard statements	H360 (100%)

H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity]

H360D (100%): May damage the unborn child [Danger Reproductive toxicity]

What the public record says

Zanubrutinib · CAS 1691249-45-2 · C27H29N5O3. UNII AG9MHG098Z.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.